Search

The results of studies are presented of the dynamics on survival of patients with malignant tumors of the brain and other parts of central nervous system (C70-72) over a long period at the population level (St. Petersburg and Arkhangelsk region) by sex, age, histological structure and other parameters.

For the first time in Russia the dynamics of morbidity and mortality from malignant tumors of the brain and other parts of the CNS in the North-West Federal District of Russia is presented. A precise elaboration of data on cases is performed according to the database of the Population-based Cancer Registries of St. Petersburg and Arkhangelsk region.

The results of definitive radiation treatment (1988-2000) for 375 patients with inoperable non-small cell lung cancer were analyzed. Three regimens of fractionation were used: (1) accelerated fractionation (AF)--(133), 2.5 Gy, 3 days a week, to a total of 47.5--55 Gy; (2) accelerated hyperfractionation (AHF)--(93), 1.25 Gy, daily, to a total of 60-72.5 Gy and standard fractionation (SF)--(149), 2 Gy, daily, to a total of 58-68 Gy. The advantages of AHF were established as regards complete regression rate (54.9% vs. 18.6%--SF and 18.1%--AF; p(0.001), median survival (30.5(2.4 months vs. 18.9 (1%--SF (p = 0.004) and 20.4 (2.4--AF (p = 0.004)), and 3-year survival (36.6% vs. 16.7%--SF (p = 0.005) and 15.5%--AF (p = 0.005). 17.9%, 9.0% (p = 0.11) and 8.1% (p = 0.08) have survived, respectively. Overall survival in the AHF group was superior in stages IIB--III; in stage I, the results were identical. Immediate response to radical radiotherapy appeared the only statistically significant factor of survival (p = 0.005-0.008) in all the groups.

The results of definitive radiation treatment for 303 patients with inoperable esophageal cancer were analyzed. Four regimens of fractionation were used: (1) accelerated hyperfractionation (AHF) (70)--1.3 Gy, twice a day, 5 weeks, to a total of 57.2-70 Gy; (2) AHF (49)--1.5-d = 1.5 Gy to a total of 54-63 Gy; (3) AHF (37)--1.7-d = 1.7 Gy to a total of 56.1-57.83 Gy and (4) standard fractionation (SF) (147) to a total of 58-70 Gy. The complete regression rate in the AHF groups (1.3-1.7, 69, 61 and 73%, respectively) was significantly higher than in that of SF (38%) (p(0.01); the median survival in the AHF groups and SF--21, 22, 12.3 and 14.3 months, respectively, and the 5-year survival 14, 12, 4 and 0%, respectively; all the differences in the groups 1.3 and SF were significant. The common independent prognostic factors for all patients were age (p = 0.04), immediate effect of radiation therapy (p = 0.01) and the length of tumor (p = 0.02).